Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Toripalimab for Renal Preservation in UTUC
NCT06354231Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in upper urinary tract urothelial carcinoma (UTUC), sponsored by Fudan University. Started Jul 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
upper urinary tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06354231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354231.